Status: Recruiting
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.
Participants needed: 27
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Alvaro Alencar, MDUpdated: Sep 21, 2026Locations: 1
Eligibility criteria
Men and women ≥ 18 years of age [+12]
Patients receiving any other investigational agents [+22]